Lunai Bioworks acquires Clemann Group BBB delivery platform in $20M deal

Reuters03-31
<a href="https://laohu8.com/S/LNAI">Lunai Bioworks</a> acquires Clemann Group BBB delivery platform in $20M deal
  • Lunai Bioworks executed a binding $20 million transaction to acquire blood-brain barrier delivery technology and CNS Alzheimer’s drug assets from Clemann Group.
  • Consideration uses Series B convertible preferred stock with a fixed $1.50 per-share conversion price.
  • Conversion is subject to a 19.9% beneficial ownership cap.
  • Assets include a delivery platform designed to cross blood-brain barrier, with activation intended to occur inside brain.
  • Acquisition expands Lunai’s CNS pipeline beyond Alzheimer’s into other neurological disorders where brain penetration limits drug development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001731122-26-000502), on March 30, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment